Glycostem to participant the 63rd ASH Annual Meeting & Exposition virtually to present abstract online, about Clinical data of the first two acute myeloid leukemia patients enrolled in the phase I/IIa WiNK clinical trial.

Title: Allogeneic, CD34+, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients With Measurable Residual Disease

Session Date/Time:  11^th December 11, 2021 5:30 PM - 7:30 PM EST

Glycostem Chief Development Officer Volker Huppert to present at Next Generation Cell & Gene Therapy Conference about Scaling NK Manufacturing on 8^th Nov.
 

Glycostem to attend 8^th European Drug Discovery Strategic Summit in Amsterdam, Netherlands on 4^th & 5^th November 2021. 

Glycostem Chief Development Officer Volker Huppert to present 29th Oct at Cell UK 2021 organized by Oxford Global Conferences, to give a keynote speech about manufacturing scaling of CAR-NK product. This in-person event will also be streamed online.

Glycostem to present at the 2021 virtual Cord Blood Connect international congress on 30^th September 2021.

Session Topic:            Perinatal Tissues as Source Material for Novel Therapies
Session Date/Time:    30th September 2021  -  10:05 - 10:55 AM EDT / 16:05 – 16:55 PM CET
 

Glycostem to present virtually at the Advanced Therapies Connect  on 28-29th of September, 2021.